UnitedHealth, CVS Caremark, Express Scripts sued by FTC over skyrocketing insulin prices
The FTC sued UnitedHealth Group’s Optum unit, CVS Caremark and Cigna’s Express Scripts for allegedly steering diabetes patients towards higher priced insulin.
Drug middlemen illegally drive up the cost of insulin, FTC says
Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.
Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
Federal regulator hauls huge drug middlemen into court over insulin prices
The government’s antitrust watchdog on Friday sued three massive health conglomerates, accusing their drug middlemen of forcing insulin prices to skyrocket since 2012. The Federal Trade Commission claims that the middlemen — known as pharmacy benefit managers,
Federal Trade Commission sues largest drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission took action Friday against the three largest pharmacy benefit managers, accusing the companies of “engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs,
FTC sues big 3 PBMs for ‘artificially inflated’ insulin prices caused by ‘perverse’ rebating
The FTC said CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx profit at the expense of patients forced to pay more for insulin.
FTC sues three largest drug middlemen for allegedly inflating insulin prices
The Federal Trade Commission (FTC) on Friday sued the three largest pharmacy benefit managers (PBMs) for engaging in alleged anticompetitive practices that boosted profits while
FTC goes after drug middlemen for allegedly jacking up insulin prices
The Big Three handle at least 80% of the country’s insulin prescriptions. The price of insulin has exponentially increased in recent years. Now, the Federal Trade Commission (FTC) is suing three companies over allegedly inflating the cost of the drug at the expense of Americans who rely on it.
US FTC sues drug 'gatekeepers' over high insulin prices
The U.S. Federal Trade Commission sued the country's three largest pharmacy benefit managers on Friday, accusing them of steering diabetes patients towards higher priced insulin in order to reap millions of dollars in rebates from pharmaceutical companies.
FTC Sues CVS, Cigna, UnitedHealth over insulin prices
The enforcement action is part of an escalating conflict between the FTC and the three pharmacy benefit managers that together control about 80% of prescriptions filled in the US.
American Pharmacists Association applauds FTC action on PBMs' alleged inflation of insulin drug prices
Hogue, PharmD, FAPhA, FNAP, FFIP, executive vice president and CEO of APhA, commended the Federal Trade Commission's (FTC) action today against alleged practices by large vertically integrated pharmacy benefit managers (PBMs) "for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs,
Are CVS Health, Cigna, and UnitedHealth Group Stocks Bad News Buys With the FTC's PBM Crackdown?
Unsurprisingly, CVS Health, Cigna, and UnitedHealth Group stocks fell last week after the FTC lawsuit announcement. But are ...
FTC Takes Legal Action Against Three Largest PBMs Over High Insulin Prices
Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug ...
Modern Healthcare3d
FTC targets 3 biggest PBMs over insulin rebates
The Federal Trade Commission's administrative complaint follows an interim report from the agency regarding PBM practices.
STAT23h
The biotech news you need to start the week
A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...
Health care giant sues to stop antitrust probe of pharmacy drug middlemen
The owner of one of the three largest pharmacy middlemen in the United States last week filed suit to quash an attempt by the ...